Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Market Cap: US$20.0b

Teva Pharmaceutical Industries Management

Management criteria checks 2/4

Teva Pharmaceutical Industries' CEO is Richard Francis, appointed in Jan 2023, has a tenure of 1.92 years. total yearly compensation is $25.71M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $2.17M. The average tenure of the management team and the board of directors is 2.8 years and 7.4 years respectively.

Key information

Richard Francis

Chief executive officer

US$25.7m

Total compensation

CEO salary percentage6.2%
CEO tenure1.9yrs
CEO ownership0.01%
Management average tenure2.8yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Dec 04

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

CEO Compensation Analysis

How has Richard Francis's remuneration changed compared to Teva Pharmaceutical Industries's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$959m

Jun 30 2024n/an/a

-US$453m

Mar 31 2024n/an/a

-US$478m

Dec 31 2023US$26mUS$2m

-US$559m

Compensation vs Market: Richard's total compensation ($USD25.71M) is above average for companies of similar size in the US market ($USD12.63M).

Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.


CEO

Richard Francis (56 yo)

1.9yrs

Tenure

US$25,706,880

Compensation

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...


Leadership Team

NamePositionTenureCompensationOwnership
Richard Francis
President1.9yrsUS$25.71m0.011%
$ 2.2m
Eliyahu Kalif
Executive VP & CFO5yrsUS$4.94m0.064%
$ 12.7m
Mark Sabag
Executive Vice President of International Markets Commercial3.3yrsUS$3.73m0.028%
$ 5.6m
Richard Daniell
Executive Vice President of European Commercial7.1yrsUS$5.16m0%
$ 0
Matthew Shields
Executive Vice President of Global Operationsless than a yearno datano data
Amir Weiss
Senior VP & Chief Accounting Officer3.1yrsno data0.00046%
$ 91.9k
Ran Meir
Head of Investor Relationsno datano datano data
Kathleen Veit
Senior Vice President2.4yrsno datano data
David Mcavoy
Executive VP & Chief Legal Officerless than a yearno datano data
Placid Jover
Executive VP & CHROless than a yearno datano data
Kevin Mannix
Senior Vice President of Investor Relationsno datano datano data
Nir Baron
Senior VP & Chief Internal Auditor10.6yrsno datano data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: TEVA's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Francis
Presidentno dataUS$25.71m0.011%
$ 2.2m
Sol Barer
Independent Chairman of the Board9.9yrsUS$539.99k0.036%
$ 7.2m
Amir Elstein
Independent Director15.9yrsUS$340.00k0.18%
$ 36.9m
Gerald Lieberman
Independent Director9.3yrsUS$355.00k0.0093%
$ 1.9m
Roberto Mignone
Independent Director7.4yrsUS$340.00k0.0084%
$ 1.7m
Rosemary Crane
Independent Director9.3yrsUS$330.00k0.0091%
$ 1.8m
Janet Vergis
Independent Director4.5yrsUS$325.46k0.0056%
$ 1.1m
Chen Lichtenstein
Directorno datano datano data
Tal Zaks
Independent Director3.2yrsUS$330.00k0.0043%
$ 864.7k
Perry Nisen
Independent Director7.4yrsUS$327.87k0.0084%
$ 1.7m
Ronit Satchi-Fainaro
Independent Director6.5yrsUS$315.25k0.0078%
$ 1.6m
Varda Shalev
Independent Director1.3yrsUS$176.66k0.0011%
$ 225.6k

7.4yrs

Average Tenure

62yo

Average Age

Experienced Board: TEVA's board of directors are considered experienced (7.4 years average tenure).